168 related articles for article (PubMed ID: 36951543)
21. Characteristics and Prognostic Factors for Patients With HER2-overexpressing Breast Cancer and Brain Metastases in the Era of HER2-targeted Therapy: An Argument for Earlier Detection.
Morikawa A; Wang R; Patil S; Diab A; Yang J; Hudis CA; McArthur HL; Beal K; Seidman AD
Clin Breast Cancer; 2018 Oct; 18(5):353-361. PubMed ID: 29337140
[TBL] [Abstract][Full Text] [Related]
22. Slowly Progressive Bone Marrow Metastasis of Gastric Cancer Followed-up Without Treatment.
Suto H; Inui Y; Okamura A
In Vivo; 2023; 37(3):1389-1393. PubMed ID: 37103098
[TBL] [Abstract][Full Text] [Related]
23. Characteristics of patients with brain metastases from human epidermal growth factor receptor 2-positive breast cancer: subanalysis of Brain Metastases in Breast Cancer Registry.
Laakmann E; Witzel I; Neunhöffer T; Park-Simon TW; Weide R; Riecke K; Polasik A; Schmidt M; Puppe J; Mundhenke C; Lübbe K; Hesse T; Thill M; Zahm DM; Denkert C; Fehm T; Nekljudova V; Rey J; Loibl S; Müller V
ESMO Open; 2022 Jun; 7(3):100495. PubMed ID: 35653983
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of human epidermal growth factor receptor 2 status and systemic therapy in breast cancer with brain metastases treated with radiotherapy.
Tsuruoka S; Kataoka M; Uwatsu K; Makita K; Tsuruoka K; Takata N; Ishikawa H; Hamamoto Y; Mochizuki T; Kido T
Asia Pac J Clin Oncol; 2023 Jun; 19(3):347-354. PubMed ID: 36281655
[TBL] [Abstract][Full Text] [Related]
25. CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.
Gao JJ; Cheng J; Bloomquist E; Sanchez J; Wedam SB; Singh H; Amiri-Kordestani L; Ibrahim A; Sridhara R; Goldberg KB; Theoret MR; Kluetz PG; Blumenthal GM; Pazdur R; Beaver JA; Prowell TM
Lancet Oncol; 2020 Feb; 21(2):250-260. PubMed ID: 31859246
[TBL] [Abstract][Full Text] [Related]
26. Chemokine receptor CXCR4 expression in breast cancer as a potential predictive marker of isolated tumor cells in bone marrow.
Cabioglu N; Sahin A; Doucet M; Yavuz E; Igci A; O Yildirim E; Aktas E; Bilgic S; Kiran B; Deniz G; Price JE
Clin Exp Metastasis; 2005; 22(1):39-46. PubMed ID: 16132577
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of bone marrow micrometastasis in patients with operable esophageal squamous cell carcinoma: a long-term follow-up study.
Chen SB; Su XD; Ma GW; Lin P; Wen J; Wang FX; Zhang H; Fu JH; Zhang X
J Thorac Oncol; 2014 Aug; 9(8):1207-13. PubMed ID: 25157775
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive review of solid tumor bone marrow metastasis.
Zhang L; Chen F; Xu L; Li N; Zhuo Q; Guo Y; Wang X; Wen M; Zhao Z; Li M
Crit Rev Oncol Hematol; 2024 Feb; 194():104248. PubMed ID: 38145832
[TBL] [Abstract][Full Text] [Related]
29. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
[TBL] [Abstract][Full Text] [Related]
30. Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy.
Jia Z; Dai M; Shang Y; Li Y; Li Z
BMC Cancer; 2023 Jan; 23(1):93. PubMed ID: 36703144
[TBL] [Abstract][Full Text] [Related]
31. Systemic therapy and prognosis of older patients with stage II/III breast cancer: A large-scale analysis of the Japanese Breast Cancer Registry.
Yamada A; Kumamaru H; Shimizu C; Taira N; Nakayama K; Miyashita M; Honma N; Miyata H; Endo I; Saji S; Sawaki M
Eur J Cancer; 2021 Sep; 154():157-166. PubMed ID: 34293663
[TBL] [Abstract][Full Text] [Related]
32. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.
Cote RJ; Rosen PP; Lesser ML; Old LJ; Osborne MP
J Clin Oncol; 1991 Oct; 9(10):1749-56. PubMed ID: 1919627
[TBL] [Abstract][Full Text] [Related]
33. Clinical features and treatment of patients with lung adenocarcinoma with bone marrow metastasis.
Wang D; Luo Y; Shen D; Yang L; Liu HY; Che YQ
Tumori; 2019 Oct; 105(5):388-393. PubMed ID: 30931812
[TBL] [Abstract][Full Text] [Related]
34. Assessment of tumor characteristics and factors affecting survival in patients with primary metastatic breast carcinoma: a Multicenter Study of the Anatolian Society of Medical Oncology.
Uyeturk U; Oksuzoglu B; Akman T; Turker I; Sener N; Tastekin D; Bal O; Berk V; Arslan UY; Urakci Z; Bilir C; Yilmaz U; Yazilitas D; Ulas A; Sonmez OU; Budakoglu B; Cihan S; Uysal M
Med Oncol; 2014 Apr; 31(4):929. PubMed ID: 24659267
[TBL] [Abstract][Full Text] [Related]
35. Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Gilje B; Nordgård O; Tjensvoll K; Janssen EA; Søiland H; Smaaland R; Baak JP
Breast Cancer Res Treat; 2011 Jul; 128(1):137-46. PubMed ID: 21476002
[TBL] [Abstract][Full Text] [Related]
36. New brain metastases after whole-brain radiotherapy of initial brain metastases in breast cancer patients: the significance of molecular subtypes (KROG 16-12).
Kim JS; Kim K; Jung W; Shin KH; Im SA; Kim HJ; Kim YB; Chang JS; Kim JH; Choi DH; Park YH; Kim DY; Kim TH; Choi BO; Lee SW; Kim S; Kwon J; Kang KM; Chung WK; Kim KS; Yoon WS; Kim JH; Cha J; Oh YK; Kim IA
Breast Cancer Res Treat; 2021 Apr; 186(2):453-462. PubMed ID: 33392845
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of bone marrow microinvolvement in nonsmall cell lung carcinoma.
Hsu CP; Shai SE; Hsia JY; Chen CY
Cancer; 2004 Feb; 100(4):794-800. PubMed ID: 14770436
[TBL] [Abstract][Full Text] [Related]
38. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Miglietta F; Dieci MV; Tsvetkova V; Griguolo G; Vernaci G; Menichetti A; Faggioni G; Giarratano T; Mioranza E; Genovesi E; Cumerlato E; Bottosso M; Saibene T; Michieletto S; Lo Mele M; Conte P; Guarneri V
Oncologist; 2020 Sep; 25(9):e1355-e1362. PubMed ID: 32618068
[TBL] [Abstract][Full Text] [Related]
39. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
40. [Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer].
Wang Y; Zhang S; Zhang H; Liang L; Xu L; Cheng YJ; Duan XN; Liu YH; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Oct; 54(5):853-862. PubMed ID: 36241228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
